ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant- Busting the Myth of Wound Infection Due to mTOR Inhibitors.

S.-C. Hsu, A. Thorat, L.-B. Jeng, H.-R. Yang, P.-C. Li, C.-C. Yeh, T.-H. Chen, K.-S. Poon.

Organ Transplantation, China Medical University Hospital, Taichung, Taiwan

Meeting: 2017 American Transplant Congress

Abstract number: D208

Keywords: Immunosuppression

Session Information

Date: Tuesday, May 2, 2017

Session Name: Poster Session D: Liver: Immunosuppression and Rejection

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Assessing the Role of Everolimus in Reducing Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation for Patients within UCSF Criteria: Re-Inventing the Role of Mammalian Target of Rapamycine Inhibitors.
  • Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.

Background:

Safety of everolimus(EVR)when used at an early stage after living donor liver transplantation (LDLT) was proven by many centers including ours. However, the opponents of this drug argue for possible increased rates of wound infections after transplant surgery.The safety of use of mTOR inhibitors,mainly EVR,in patients undergoing major surgeries in post-transplant period for non-transplant related causes has not been elucidated and the factual data related to EVR role in wound infection remains scarce.In this retrospective analysis, we determined the possible impact of EVR when used as primary immunosuppressant on the wound infection and/or wound dehiscence.

Materials and methods:

From August 2002 to January 2016, 695 LDLT surgeries were performed at China Medical University Hospital, Taiwan.EVR has been used in 325 liver transplant recipients since February 2012 till January 2016.A total of 54 liver transplant recipients underwent non-transplant surgeries in post-operative period ranging from 2nd post-transplant month to 4 years post-transplantation.

Results:

54 liver transplant recipients (Male:Female, 41:13) received non-transplant surgeries as early as 2nd postoperative month till 4 year post-transplantation.The mean age of the study cohort was 55 + 8 (range, 27 to 72 years). Eleven patients (n=11) underwent minor surgical procedures and 43 patients underwent major surgeries that included major laparotomies, thoracic, orthopaedic and neurosurgeries. The EVR dose was 1 ± 0.50 mg/day against an average EVR trough level of 3.57 ± 1.24 ng/ml (Range, <1.5-6.3) at the time of non-transplant surgical procedures. The average trough level of tacrolimus in these patients at 3 months,12 months post-transplant period was 8.03 ± 3.85 ng/ml and 6 ± 2.37 ng/ml, respectively.None of the patients of the study cohort develop wound infection or wound dehiscence. There were no reported incidence of hepatic artery thrombosis among the patients using EVR.None of these patients that underwent major orthopedic surgeries showed delayed fracture union or non-union.

Conclusion:

EVR based immunosuppression was safe in LDLT recipients undergoing non-transplant surgeries. There was no incidence of wound infection or wound dehiscence. Our large scale findings suggest no correlation of EVR use and reported post-operative wound infections in recipients.

CITATION INFORMATION: Hsu S.-C, Thorat A, Jeng L.-B, Yang H.-R, Li P.-C, Yeh C.-C, Chen T.-H, Poon K.-S. Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant- Busting the Myth of Wound Infection Due to mTOR Inhibitors. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hsu S-C, Thorat A, Jeng L-B, Yang H-R, Li P-C, Yeh C-C, Chen T-H, Poon K-S. Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant- Busting the Myth of Wound Infection Due to mTOR Inhibitors. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/liver-transplant-recipients-undergoing-non-transplant-surgeries-and-everolimus-use-as-primary-immunosuppressant-busting-the-myth-of-wound-infection-due-to-mtor-inhibitors/. Accessed April 22, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.